AI CAN HELP DOCTORS
FIGHT CORONAVIRUS.

Envisionit Deep AI™ is committed to fighting the impact of COVID-19.

RADIFY™

We’ve developed RADIFY™ to enable radiologists to diagnose more images, more consistently and in less time – whilst prioritising care for people who need it most.

Free of charge to support hospitals and doctors

In response to the COVID-19 outbreak, we would like to offer RADIFY™ to any public and private organisation using X-ray in the identification and treatment of COVID-19 pneumonia.

A chest X-Ray is the first line of investigation for pneumonia. It’s the most readily available, quick and cost-effective imaging tool for the diagnosis of pneumonia – the number one killer of patients with COVID-19 and TB.

RADIFY™ detects 20 major abnormalities on chest X-rays – including TB and COVID 19 pneumonia related pathologies. It can label and prioritise over 2000 x-rays per minute.

Above is an image of a patient with known covid19 pneumonia. Multifocal consolidation detected by RADIFY.

A chest X-Ray is the first line of investigation for pneumonia. It’s the most readily available, quick and cost-effective imaging tool for the diagnosis of pneumonia – the number one killer of patients with COVID-19 and TB.

Above is an image of a patient with known covid19 pneumonia. Multifocal consolidation detected by RADIFY.

RADIFY™ detects 20 major abnormalities on chest X-rays – including TB and COVID 19 pneumonia related pathologies. It can label and prioritise over 2000 x-rays per minute.

RADIFY™ use case 1.

A 76-year-old male presented with chest pain and dyspnoea. Patchy infiltrates in the right and left upper zones with air space opacification noted in the right midzone and left lower zone. RADIFY™ has detected the lesions with bounding boxes in the region of interest.

Result: High probability of pneumonia

RADIFY™ - use case 1.

A 76-year-old male presented with chest pain and dyspnoea. Patchy infiltrates in the right and left upper zones with air space opacification noted in the right midzone and left lower zone. RADIFY™ has detected the lesions with bounding boxes in the region of interest.

Result: High probability of pneumonia

Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS)

A total of 1.4 million people died from TB in 2019

including 208 000 people with HIV

RADIFY™ for TB

In 2019, an estimated 10 million people fell ill with tuberculosis (TB) worldwide, of which, 1.2 million where children, yet TB is curable and preventable.

An estimated 1.4 million fewer people received care for tuberculosis (TB) in 2020 than in 2019, according to preliminary data compiled by the World Health Organization (WHO) from over 80 countries- a reduction of 21% from 2019.

The countries with the biggest relative gaps were Indonesia (42%), South Africa (41%), Philippines (37%) and India (25%).

RADIFY™ for TB , identifies pathologies on chest x-rays and triages the patients with high, intermediate and low probability of TB in children and adults.

WHO now recommends CAD with chest x-rays to fight tuberculosis!

RADIFY™ - use case 2.

A 10 year old child with high probability of Tuberculosis detected by RADIFY™.

Bilateral lymphadenopathy and bi-basal areas of confluent consolidation highlighted by RADIFY™.

How we can help public
hospitals and private practices:

How we can help public hospitals and private practices:

  • Use to prioritise scans during case overload.
  • Use with portable x-ray machines to monitor progress of symptoms at point of care.
  • Use when regular monitoring is required among patients showing mild symptoms, in order to identify and/or triage patients by the progression of symptoms.

Let us call you back.

TRY RADIFY™

Request the Link for our Online Portal

33%

LOW
PROBABILITY

63%

INTERMEDIATE
PROBABILITY

88%

HIGH
PROBABILITY

RADIFY for Chest X-Rays

Data privacy is a human right. Envisionit Deep AI™ is committed to the privacy and confidentiality of information provided to us in compliance with all relevant legislation, including the Protection of Personal Information Act, 2013 (“POPI”) and General Data Protection Regulation (GDPR) (EU) 2016/679.